EphA7 Activators
EphA7 activators form a diverse array of chemicals, each engaging distinct pathways to modulate EphA7 signaling. Fasudil, for instance, achieves indirect activation by targeting the Rho/ROCK pathway. This influences cytoskeletal dynamics and cell motility, ultimately impacting EphA7 activity. Prostaglandin E2 (PGE2) takes a different route, activating EphA7 through the cyclic AMP (cAMP) pathway. The initiation of downstream signaling events serves as a trigger for EphA7 modulation. Forskolin and dibutyryl cyclic AMP (db-cAMP) contribute to this modulation by mimicking cAMP, indirectly influencing EphA7 and shaping cellular responses. Another avenue involves 8-Bromoguanosine 3',5'-cyclic monophosphate (8-Br-cGMP), which activates EphA7 through the cyclic GMP (cGMP) pathway.
Retinoic acid employs the retinoic acid receptor (RAR) pathway to activate EphA7, inducing transcriptional changes that impact the receptor's activity. Cyclic AMP (cAMP) serves as a direct activator, acting as a second messenger in EphA7 signaling. The cAMP analog, 6-Bnz-cAMP, mimics these actions, affecting EphA7 activity. H89, acting as a protein kinase A (PKA) inhibitor, indirectly activates EphA7 by disrupting PKA-mediated phosphorylation events. Y-27632, a Rho kinase (ROCK) inhibitor, takes the indirect route by modulating the Rho/ROCK pathway, influencing EphA7 through alterations in cellular architecture and signal transduction. Similarly, cilostamide, a phosphodiesterase inhibitor, indirectly activates EphA7 by blocking cAMP degradation, elevating cAMP levels and subsequently modulating EphA7 activity. These diverse activators provide researchers with powerful tools to selectively influence EphA7 signaling, offering a nuanced understanding of its role in various cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) activates EphA7 by stimulating the cyclic AMP (cAMP) pathway. PGE2 binds to its receptors, initiating a cascade of events that elevate intracellular cAMP levels. This, in turn, activates downstream signaling pathways, ultimately leading to EphA7 modulation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin, an adenylate cyclase activator, indirectly activates EphA7 by increasing intracellular cAMP levels. Elevated cAMP triggers downstream signaling cascades, modulating EphA7 activity and influencing cellular responses mediated by this receptor. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl cyclic AMP (db-cAMP) is a cell-permeable analog of cAMP that activates EphA7. By mimicking the actions of cAMP, db-cAMP influences cellular signaling pathways, leading to the modulation of EphA7 activity and affecting processes regulated by this receptor. | ||||||
8-Bromo-cGMP | 51116-01-9 | sc-200316 sc-200316A | 10 mg 50 mg | $104.00 $354.00 | 7 | |
8-Bromoguanosine 3',5'-cyclic monophosphate (8-Br-cGMP) activates EphA7 by stimulating the cyclic GMP (cGMP) pathway. This compound influences intracellular signaling events, ultimately leading to the modulation of EphA7 and affecting cellular responses associated with this receptor. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid activates EphA7 through the retinoic acid receptor (RAR) pathway. Upon binding to RAR, retinoic acid induces transcriptional changes that influence EphA7 expression and activity, providing a mechanism for the modulation of EphA7-mediated cellular responses. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Cyclic AMP (cAMP) directly activates EphA7 by serving as a second messenger in intracellular signaling. Elevated cAMP levels influence downstream pathways, leading to the modulation of EphA7 activity and affecting cellular responses mediated by this receptor. | ||||||
Adenosine 3′,5′-cyclic Monophosphate, N6-Benzoyl-, Sodium Salt | 30275-80-0 | sc-300167 | 10 µmol | $324.00 | 1 | |
6-Bnz-cAMP, a cAMP analog, activates EphA7 by mimicking the actions of cAMP. This compound influences intracellular signaling pathways, leading to the modulation of EphA7 activity and affecting cellular responses associated with this receptor. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632, a Rho kinase (ROCK) inhibitor, indirectly activates EphA7 by modulating the Rho/ROCK pathway. This compound influences cytoskeletal dynamics and cell motility, leading to EphA7 activation through alterations in cellular architecture and signal transduction. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide, a phosphodiesterase inhibitor, indirectly activates EphA7 by increasing intracellular cAMP levels. By preventing cAMP degradation, cilostamide elevates cAMP, leading to downstream signaling events that modulate EphA7 activity and cellular responses mediated by this receptor. | ||||||